Advancing Treatment of Disease with Innovative protein therapeutics and Technologies

Targeted treatment against liver cancer

TBI 302 is a hemoglobin-conjugated floxuridine compound undergoing clinical studies for the treatment of liver cancer. Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related deaths globally1. There continues to exist unmet medical needs in the treatment of HCC for the following reasons:

  • Current treatments are often ineffective for patients where potentially curative transplant or resection surgery is not an option
  • Current standard chemotherapy offers only modest survival advantages (approx. 3 months) and no benefit in terms of patient quality of life1
  • Floxuridine (a cytotoxic fluoropyrimidine nucleoside analog) has a narrow margin of safety to obtain efficacy and a potential for undesirable toxicity if not controlled. In order to avoid systemic toxicities, it is currently administered through invasive infusion via the hepatic artery

The inherent liver-targeting properties of TBI 302 offers the possibility of increased efficacy and safety and may improve treatment outcomes and quality of life for liver cancer patients where surgery is not an option and who remain poorly served by current therapies.

The US Food and Drug Administration (FDA) has given Therapure Innovations’ approval to proceed with a Phase 1 clinical trial, which is an open-label, multicenter study of TBI 302, which will evaluate the safety, tolerability and pharmacokinetics of TBI 302 in patients with advanced liver cancer.

TBI 302 Mechanism of Action Video

To view video, please click on image

REFERENCES

  1. Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res.:2012 Apr;32(4):1379-86.

To learn more about our areas of research, platform technologies and pipeline products, or to explore opportunities to partner and/or collaborate with us to improve existing therapeutics, please contact us at
innovations@therapurebio.com.